This segment focuses on the research, development, and commercialization of non-invasive screening tests for colorectal cancer. Utilizing advanced molecular diagnostic technologies, New Horizon Health aims to improve early detection rates and patient outcomes. Key products include fecal occult blood test kits and innovative DNA-based screening solutions. The company conducts extensive clinical trials to validate the accuracy and effectiveness of its screening methods. By providing accessible and convenient testing options, New Horizon Health strives to reduce the burden of colorectal cancer in China. Future opportunities include expanding market reach and developing more advanced screening technologies.

This segment is dedicated to the development and marketing of innovative screening solutions for cervical cancer. New Horizon Health leverages cutting-edge technologies to create non-invasive, urine-based tests for early detection. The company collaborates with healthcare providers to ensure widespread adoption and accessibility of its screening products. Through ongoing research and development, New Horizon Health aims to improve the accuracy and convenience of cervical cancer screening, ultimately reducing the incidence and mortality rates associated with the disease. Strategic partnerships and regulatory approvals are crucial for expanding the market presence and impact of this segment.